Why does allergic contact dermatitis exist?

British Journal of Dermatology

Volumn 168, Issue 4, 2013, Pages 692-699

  McFadden, J P ^a   Puangpet, P ^a   Basketter, D A ^b   Dearman, R J ^c   Kimber, I ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b DABMEB CONSULTANCY LTD   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; CONTACT ALLERGEN; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ACNE VULGARIS; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKIN ALLERGY; SKIN INFECTION; SKIN SENSITIVITY; TH1 CELL; TH17 CELL;

ALLERGENS; BACTERIA; CYTOKINES; DERMATITIS, ALLERGIC CONTACT; HAPTENS; HUMANS; IMMUNITY, INNATE; SKIN DISEASES, VESICULOBULLOUS; TOLL-LIKE RECEPTORS;

EID: 84875434434     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12145     Document Type: Review

References (57)

1. Matzinger P,. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
2. McFadden JP, Basketter DA,. Contact allergy, irritancy and 'danger'. Contact Dermatitis 2000; 42: 123-7.
3. Kimber I, Cumberbatch M, Dearman RJ, Griffiths CE,. Danger signals and skin sensitization. Br J Dermatol 2001; 147: 613-14.
4. Esser PR, Wölfle U, Dürr C, et al. Contact sensitizers induce skin inflammation via ROS production and hyaluronic acid degradation. PLoS ONE 2011; 7: e41340.
5. McFadden JP, Dearman RJ, White JML, et al. The hapten-atopy hypothesis II: the 'cutaneous hapten paradox'. Clin Exp Allergy 2011; 41: 327-37.
6. McFadden JP, Basketter DA, Dearman RJ, Kimber IR,. Extra domain A-positive fibronectin-positive loops and their association with cutaneous inflammatory disease. Clin Dermatol 2011; 29: 257-65.
7. Martin SF,. Contact dermatitis: from pathomechanisms to immunotoxicology. Exp Dermatol 2012; 21: 382-9.
8. Martin SF,. Allergic contact dermatitis: xenoinflammation of the skin. Curr Opin Immunol 2012; 24: 1-10.
9. Freudenberg MA, Esser PR, Jakob T, et al. Innate and adaptive immune responses in contact dermatitis: analogy with infections. G Ital Dermatol Venereol 2009; 144: 173-85.
10. Di Meglio P, Perera GK, Nestle FO,. The multitasking organ: recent insights into skin immune function. Immunity 2011; 35: 857-69.
11. Rymkiwicz PD, Heng YX, Vasudev A, Larbi A,. The immune system in the aging human. Immunol Res 2012; 53: 235-50.
12. Karlberg A-T, Bergstrom MA, Borje A, et al. Allergic contact dermatitis-formation, structural requirements, and reactivity of skin sensitisers. Chem Res Toxicol 2008; 21: 53-69.
13. Peiser M, Tralau T, Heidler J, et al. Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. Cell Mol Life Sci 2012; 69: 763-81.
14. Coenraads P-J, Uter W, Diepgen T,. Epidemiology. In: Contact Dermatitis (, Johansen JD, Frosch PJ, Lepoittevin J-P, eds), 5th edn. Berlin: Springer, 2011; 193-214.
15. White JML, Gilmour NJ, Jeffries D, et al. A general population from Thailand: incidence of common allergens with emphasis on para-phenylenediamine. Clin Exp Allergy 2007; 37: 1848-53.
16. Kligman AM,. The identification of contact allergens by human assay. The maximisation test; a procedure for screening and rating contact sensitisers. J Invest Dermatol 1966; 47: 393-409.
17. Basketter DA, Kan-King-Yu D, Dierkes P, Jowsey IR,. Does irritation potency contribute to the skin sensitization potential of contact allergens? Cutan Ocul Toxicol 2007; 26: 279-86.
18. Jacobs JJ, Lehé CL, Cammans KD, et al. Assessment of contact allergens by dissociation of irritant and sensitizing properties. Toxicol In Vitro 2004; 18: 681-90.
19. Cristofaro P, Opal SM,. Role of toll-like receptors in infection and immunity. Drugs 2006; 66: 15-29.
20. Erridge C,. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 2010; 87: 989-99.
21. Kim JE, Kim B, Kim H, et al. Retinyl retinoate induces hyaluronan production and less irritation than other retinoids. J Dermatol 2010; 37: 448-54.
22. Dorner RW,. Effect of nitrogen mustard on hyaluronate. Biochem Pharmacol 1969; 18: 2339-46.
23. Poulsen JH, Cramers MK,. Dermal glycosaminoglycans characterise the primary irritant dermatitis in psoriatics and healthy individuals. Clin Chim Acta 1983; 130: 305-15.
24. Martín AP, Ortiz S, Cabalier ME, et al. Vascular endothelium express CS-1 fibronectin in allergic contact dermatitis. J Cutan Pathol 2002; 29: 347-53.
25. Martin SF, Dudda JC, Bachtanian E, et al. Toll-like receptor and IL-12 signaling control susceptibility to contact hypersensitivity. J Exp Med 2008; 205: 2151-62.
26. Ainscough JS, Frank Gerberick F, Dearman RJ, Kimber I,. Danger, intracellular signaling, and the orchestration of dendritic cell function in skin sensitization. J Immunotoxicol, 2012. doi:10.3109/1547691X.2012.711782. [Epub ahead of print].
27. Kaplan DH, Igyarto BZ, Gaspari AA,. Early immune events in the induction of allergic contact dermatitis. Nat Rev Immunol 2012; 12: 114-24.
28. Sutterwate FS, Ogura Y, Sczepanik M, et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of Caspase-1. Immunity 2006; 24: 317-27.
29. Watanabe H, Gaide O, Petrilli V, et al. Activation of the IL-1β-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 2007; 127: 1956-63.
30. Weber FC, Esser PR, Müller T, et al. Lack of the purinergic receptor P2X(7) results in resistance to contact hypersensitivity. J Exp Med 2010; 207: 2609-19.
31. Cumberbatch M, Dearman RJ, Kimber I,. Langerhans cells require signals from both tumour necrosis factor-α and inerleukin-1β for migration. Immunology 1997; 92: 388-95.
32. Sandig H, McDonald J, Gilmour J, et al. Fibronectin is a Th1-specific molecule in human subjects. J Allergy Clin Immunol 2009; 124: 528-35.
33. Bollyky PL, Evanko SP, Wu RP, et al. Th1 cytokines promote T-cell binding to antigen-presenting cells via enhanced hyaluronan production and accumulation at the immune synapse. Cell Mol Immunol 2010; 7: 211-20.
34. Man MQ, Hatano Y, Lee SH, et al. Characterisation of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol 2008; 128: 79-86.
35. Padilla IM, Burgos L,. Aminoglycoside antibiotics: structure, functions and effects on in vitro plant culture and genetic transformation protocols. Plant Cell Rep 2010; 29: 1203-13.
36. Goh CL,. Contact sensitivity to topical antibiotics. (II) Sensitizing potential of some topical antibiotics. Contact Dermatitis 1989; 21: 166-71.
37. Smith RH, Messner P, Lamontagne L, et al. Induction of T-cell immunity to oligosaccharide antigens immobilized on crystalline bacterial surface layers (S-layers). Vaccine 1993; 11: 919-24.
38. Bessler WG, Heinevetter L, Wiesmüller KH, et al. Bacterial cell wall components as immunomodulators-1. Lipopeptides as adjuvants for parenteral and oral immunization. Int J Immunopharmacol 1997; 19: 547-50.
39. Coffman RL, Sher A, Seder RA,. Vaccine adjuvants: putting innate immunity to work. Cell 2010; 33: 492-503.
40. de Hora VP, Conceicao FR, Dellagostin OA, Doolan DL,. Non-toxic derivatives of LT as potent adjuvants. Vaccine 2011; 29: 1538-44.
41. Knapp S,. Update on the role of Toll-like receptors during bacterial infections and sepsis. Wien Med Wochenschr 2010; 160: 107-11.
42. Kawai T, Akira S,. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol Rev 2010; 11: 373-84.
43. Kinbara M, Sato N, Kuroishi T, et al. Allergy-inducing nickel concentration is lowered by lipopolysaccharide at both the sensitization and elicitation steps in a murine model. Br J Dermatol 2011; 164: 356-62.
44. Hierholzer S, Hierholzer G,. Allergy to metals following osteosynthesis. Unfallchirurgie 1982; 8: 347-52.
45. Williams HC, Dellavelle RP, Garner S,. Acne vulgaris. Lancet 2012; 379: 361-72.
46. Whitfeld M, Gunasingam N, Leow LJ, et al. Staphylococcal epidermis: a possible role in the pustules of rosacea. J Am Acad Dermatol 2011; 64: 49-52.
47. Lazaridou E, Giannopoulou C, Fotiadou C, et al. The potential role of microorganisms in the development of rosacea. J Dtsch Dermatol Ges 2011; 9: 21-5.
48. Satorius K, Killasli H, Oprica C, et al. Bacteriology of hidradenitis suppurativa exacerbations and deep tissue culture during carbon dioxide laser treatment. Br J Dermatol 2012; 166: 879-83.
49. Akamatsu H, Niwa Y, Matsunaga K,. Effect of palmitic acid on neutrophil function. Int J Dermatol 2001; 40: 640-3.
50. Nakatsuji T, Kao MC, Zhang L, et al. Sebum free acids enhance the innate immune defence of human sebocytes by upregulating beta-defensin 2 expression. J Invest Dermatol 2010; 130: 985-94.
51. Grech I, Giatrakou S, Damoraki G, et al. Single nucleotide polymorphisms of toll-like receptor-4 protect against acne conglobata. J Eur Acad Dermatol Venereol 2012; 26: 1538-43.
52. Jeong E, Hong JW, Min JA, et al. Topical ALA-photodynamic therapy for acne can induce apoptosis of sebocytes and down-regulate their TLR2 and TLR4 expression. Ann Dermatol 2011; 23: 23-32.
53. Yamasaki K, Kanad A, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol 2011; 131: 688-97.
54. Hunger RE, Surow AM, Hassan AS, et al. Toll-like receptor 2 is highly expressed in lesions of acne inverse and colocalises with C-type lectin receptor. Br J Dermatol 2008; 158: 691-7.
55. Sansonetti PJ,. To be or not to be a pathogen: that is the mucosally relevant question. Mucosal Immunol 2011; 4: 8-14.
56. Dunn-Siegrist I, Tissieres P, Drifte G, et al. Toll-like receptor activation of human cells by synthetic triacylated lipid A-like molecules. J Biol Chem 2012; 287: 16121-3.
57. Schmidt M, Raghaven B, Muller V, et al. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 2010; 11: 814-19.